These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29198449)

  • 1. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
    Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
    Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE; Mesure R
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
    Young A; Anzures-Cabrera J; Derks M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
    Friedrich C; Port A; Ring A; Graefe-Mody U; Giessmann T; Iovino M; Woerle HJ
    Clin Drug Investig; 2011; 31(9):643-53. PubMed ID: 21714581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
    Dienel A; Klement S; Müller F
    Arzneimittelforschung; 2004; 54(3):152-9. PubMed ID: 15112861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
    Kapitza C; Nosek L; Jensen L; Hartvig H; Jensen CB; Flint A
    J Clin Pharmacol; 2015 May; 55(5):497-504. PubMed ID: 25475122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.
    Falcão A; Vaz-da-Silva M; Gama H; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Aug; 105(3):368-76. PubMed ID: 23570863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
    Elgart A; Zur AA; Mimrod D; Dror V; Bar-Ilan O; Korver T; Spiegelstein O
    Eur J Clin Pharmacol; 2019 Jan; 75(1):41-49. PubMed ID: 30191262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Sabo JP; Lang B; Elgadi M; Huang F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
    Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
    J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.